Psoriasis Workup Expands Beyond Skin: SDPA 2026 Highlights Systemic Risk

Psoriasis is a chronic inflammatory skin condition affecting approximately 2-3% of the global population.¹ While its primary manifestations are erythematous, scaly plaques on the skin and psoriatic arthritis (PsA) in up to 30% of patients,² it is increasingly recognized as a systemic inflammatory disease. This systemic inflammation contributes to a range of comorbidities that significantly impact patient morbidity and mortality.³ The SDPA 2026 discussions underscored the necessity for clinicians to adopt a holistic approach to psoriasis management, moving beyond topical or localized treatments to address the broader systemic implications. This includes a proactive strategy for identifying and managing associated conditions, which often manifest silently or are overlooked in routine dermatological assessments.⁴

Systemic Comorbidities and Expanded Workup

The systemic inflammatory state in psoriasis patients is associated with an elevated risk of cardiovascular disease (CVD), including myocardial infarction and stroke.⁵ This risk is particularly pronounced in patients with severe psoriasis, who may have a hazard ratio (HR) for major adverse cardiovascular events (MACE) up to 1.5 (95% CI, 1.3-1.7) compared to the general population, even after adjusting for traditional CVD risk factors.⁶ The underlying chronic inflammation contributes to endothelial dysfunction, accelerated atherosclerosis, and dyslipidemia.⁷ Consequently, the expanded workup for psoriasis patients should include routine screening for hypertension, dyslipidemia, and diabetes mellitus. Fasting lipid panels, blood pressure measurements, and glucose monitoring are now considered essential components of initial and ongoing assessments.⁸

Metabolic syndrome is another frequently observed comorbidity, affecting a substantial proportion of psoriasis patients.⁹ This syndrome, characterized by central obesity, hypertension, dyslipidemia, and insulin resistance, is more prevalent in individuals with psoriasis than in age-matched controls.¹⁰ The prevalence of metabolic syndrome in psoriasis patients can be as high as 40-50%, depending on the severity of skin disease.¹¹ Given this association, clinicians are advised to screen for components of metabolic syndrome, including waist circumference, blood pressure, fasting glucose, and lipid profiles. Early identification allows for timely lifestyle interventions and pharmacotherapy to mitigate long-term cardiovascular and metabolic complications.¹²

Beyond cardiovascular and metabolic concerns, psoriasis is also linked to other immune-mediated conditions. Inflammatory bowel disease (IBD), particularly Crohn's disease and ulcerative colitis, has a higher incidence in psoriasis patients.¹³ The shared genetic predispositions and inflammatory pathways between psoriasis and IBD necessitate vigilance for gastrointestinal symptoms.¹⁴ Additionally, non-alcoholic fatty liver disease (NAFLD) is more common in psoriasis patients, often correlating with disease severity and metabolic syndrome.¹⁵ Therefore, liver function tests and, in some cases, imaging studies may be warranted as part of a comprehensive evaluation.¹⁶

The SDPA 2026 discussions emphasized that this expanded workup is not merely an academic exercise but a practical necessity to improve patient outcomes. By proactively identifying and managing these comorbidities, clinicians can reduce the overall disease burden, prevent severe complications, and potentially extend the lifespan of psoriasis patients. The integration of these screening protocols into routine dermatological practice represents a significant evolution in psoriasis care, requiring interdisciplinary collaboration between dermatologists, primary care physicians, cardiologists, and endocrinologists.¹⁷